Summary
The provided claims pertain to topical hydrocortisone cream, but the available FDA label sections describe Hydrocortisone Rectal Suspension (enema) for ulcerative colitis. There is no topical cream-specific labeling available to evaluate the claims against.
Category Scores
Accurate Statements
Unsupported Statements
Topical hydrocortisone cream indications, dosing, and safety claims.
The label provided documents Hydrocortisone Rectal Suspension, not a topical hydrocortisone cream. Topical product-specific claims cannot be supported by this label.
Contradictions
Important Omissions
Topical hydrocortisone cream product labeling details (indications, dosing by age/area, contraindications, boxed warnings if any, pediatric/pregnancy safety, adverse reactions, and administration instructions) are not present in the rectal suspension label and thus not evaluable.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Low
No topical product-specific safety data was provided in the rectal suspension label; the mismatch limits ability to assess safety for a topical cream. This evaluation does not introduce new safety risks beyond the label mismatch.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
Yes |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Not Aligned
Primary Issue
Label evaluated is for Hydrocortisone Rectal Suspension, not hydrocortisone cream topical product.
Suggested Improvement
Evaluate or generate guidance strictly against the topical hydrocortisone cream label (if available). If only the rectal suspension label is accessible, clearly state that topical product claims cannot be evaluated and avoid extrapolating dosing, indications, or safety data to the topical cream. Include product-specific sections: Indications and Usage, Dosage and Administration, Contraindications, Warnings and Precautions, Adverse Reactions, and Information for Patients with explicit topical-use safety considerations.